A B S T R A C T The development of hyperphospholipidemia and hypercholesterolemia was studied in infants that required total parenteral nutrition and given a continuous infusion of Intralipid, (1) (2) (3) (4) g/kg body wt per 24 h. Detailed studies were carried out on infusion periods lasting 1-10 d. After 24 h there was a marked increase in plasma free cholesterol (68%) and phospholipid (77%) concentrations. Based on the amount of cholesterol in Intralipid, and the rate of infusion, it was estimated that at least 50% of the plasma cholesterol increment during 64-h infusions was derived from endogenous sources. By contrast, the hyperphospholipidemia could be attributed to the Intralipid as the rise in plasma was calculated to be equivalent to only 16% of the exogenous phospholipid infused. Approximately 10% of the phospholipid in Intralipid was in a triglyceride-free mesophase form with a free cholesterol:phospholipid molar ratio of 0.063. There were no systematic changes in plasma concentrations of cholesterol ester or triglyceride during Intralipid infusions. The increase in free cholesterol and phospholipid was localized in the low density lipoproteins (d = 1.006-1.063 g/ml). The presence of lipoprotein X (Lp-X) 2 Detailed analyses of Intralipid (three preparations) revealed the presence of free cholesterol (4 mg/g Intralipid triglyceride) as well as plant sterols (2 mg/g Intralipid triglyceride). Two Intralipid preparations were subjected to ultracentrifugation at saline density (1.6 x 106 g min). Analysis of the supematant and infranatant fractions obtained after tube slicing revealed that 8-12% of the total phospholipid and free cholesterol was associated with the infranatant fraction as a triglyceride-free micelle. The molar ratio of free cholesterol:phospholipid in the triglyceride-rich supernatant and the infranatant mesophase was 0.063.
INTRODUCTION
Although fat emulsions are needed to supply additional calories and to avoid essential fatty acid deficiency during intravenous nutrition in the neonate (1) , their use has been associated with various hyperlipidemias. Intralipid, the most commonly used parenteral fat solution, is an emulsion of soybean triglyceride that contains 1.2% egg lecithin as a stabilizing agent. Hypertriglyceridemia, defined as plasma triglyceride concentration exceeding 100 mg/dl, has been noted in small-for-gestational-age infants (2, 3) , and in the premature, < 32 wk (3, 4) ; and is manifested by a delay in clearing bolus injections or infusions (4 h) of Intralipid. This apparent intolerance to parenteral lipid has been attributed to reduced hydrolysis of Intralipid triglyceride as well as to a diminished uptake and utilization of the liberated FFA in peripheral tissue. In recent reports a rise in plasma free cholesterol and phospholipid concentrations has been observed in both the neonate (5, 6) and adults (7) (8) (9) after infusions of Intralipid. In view of these observations a detailed study was undertaken to investigate the alterations in plasma lipids and lipoproteins during continuous administration of Intralipid to neonates dependent upon total parenteral nutrition (TPN) .' On the basis of this study it is suggested that the hypercholesterolemia is a consequence of phospholipid overload, which causes the accumulation of a lipoprotein with chemical composition and electrophoretic properties of lipoprotein X.
METHODS
Patients. The infants studied required TPN for a variety of congenital and acquired gastrointestinal anomalies. All were appropriate for gestational age that ranged from 26-to 40-wk gestation at birth, and were from 4-d-to 3-wk-old when Intralipid (Cutter Medical, Div. Cutter Laboratories, Berkeley, Calif.) was started. Intralipid2 (containing per 100 ml: 10 g soybean triglyceride, 1.2 g egg lecithin, and 2.5 g glycerol) was administered via a scalp vein needle using a Sage syringe pump (model 255, Sage Instruments Div., Orion Research Inc., Cambridge, Mass.) to maintain a constant rate of infusion. The infants received glucose and casein hydrolysate for at least 24 h before and during the period of Intralipid infusion. None of the infants was acidotic, septic, or had bilirubin concentrations exceeding 5 mg/100 ml. Infants with minor elevations in direct reacting bilirubin (<2 mg/100 ml) were included because these infants did not differ from those in whom there was no such increase.
Based on Intralipid tolerance tests, individual infusion rates were calculated3 for the majority of infants studied as follows: a bolus injection of 200 mg of Intralipid triglyceride/ kg body wt was given; the fractional elimination constant, K2, and the Intralipid volume ofdistribution were determined, and these values were applied to the formula of the plateau principle (10, 11) to calculate an infusion rate to achieve a steady plasma Intralipid concentration of 100 mg/dl or less. This target concentration was chosen to avoid hyperlipidemia (12) .3 All the infants in this study received, by continuous infusion, [1] [2] [3] [4] 2 Detailed analyses of Intralipid (three preparations) revealed the presence of free cholesterol (4 mg/g Intralipid triglyceride) as well as plant sterols (2 mg/g Intralipid triglyceride). Two Intralipid preparations were subjected to ultracentrifugation at saline density (1.6 x 106 g min). Analysis of the supematant and infranatant fractions obtained after tube slicing revealed that 8-12% of the total phospholipid and free cholesterol was associated with the infranatant fraction as a triglyceride-free micelle. The molar ratio of free cholesterol:phospholipid in the triglyceride-rich supernatant and the infranatant mesophase was 0.063.
3Griffin, E. A., M. H. Bryan, and A. Angel. Intralipid tolerance tests and continuous infusion in neonates. Manuscript submitted for publication. cellulose nitrate centrifuge tubes. Plasma (0.6-1.0 ml) was overlayered with saline, pH 7.4 (d = 1.006 g/ml) and centrifuged at 106,000 g for 18 h. A supematant fraction (0.8 ml) and an infranatant fraction (1.2 ml) were quantitatively collected by tube slicing. The infranatant fraction was adjusted to d 1.063 and centrifuged at 106,000 g for 24 h to obtain low density lipoproteins (LDL) in the supernatant fraction. For studies involving protein analyses, LDL was washed once. The infranatant was adjusted to d = 1.21 g/ml and centrifuged for 42 h at 106,000 g to obtain high density lipoproteins (HDL).
The lipoproteins ofd 1.006-1.063 were further resolved by hydroxylapatite column chromatography as described by Kostner et al. (14) for the isolation of lipoprotein X (Lp-X) from cholestatic patients. In these studies, columns were eluted at 0.1 M phosphate buffer (pH 6.8) to obtain Lp-X and at 0.65 M phosphate (pH 6.8) to obtain "residual LDL." Because initial studies demonstrated that the elution profiles monitored by optical density (280 nm) or cholesterol content were identical, optical density was routinely used.
Lipoprotein electrophoresis on agarose gel was carried out by the method of Maguire and Breckenridge (15) , whereas electrophoresis on agar, for the detection of Lp-X, was performed as described by Seidel et al. (16) . Apoproteins from various lipoproteins were analyzed by polyacrylamide gel electrophoresis after treatment of the lipoprotein with tetramethylurea (TMU) as described by Kane (17) . Apoprotein that was insoluble in TMU was assumed to be apoprotein (apo)B. Apoprotein components were identified on polyacrylamide gels by comigration with purified apoproteins or by their relative electrophoretic mobility.
Apoproteins were also characterized by isoelectric focusing. Lyophilized lipoproteins were delipidated with three extractions of ethanol:ether 3:1 (vol/vol). The Pagnan et al. (18) with the following modifications. A linear gradient between pH 3 and 7 was achieved by using ampholytes composed of pH 3-5, 4-6, and 5-7 in a proportion of 1:2:2 (vol/vol per vol). Gels (0.5 x 12 cm) were prefocused for 1 h at 100 V. The samples (50-to 100-,ig urea-soluble protein) were applied in 8 M urea and overlayered with an aqueous solution that contained 1% ampholyte mixture and 5% sucrose. The gels were focused for 250 V for 16 h and then stained as described elsewhere (19) . For determination of the pH gradient a gel, lacking sample was subjected to focusing and then cut into 5-mm segments that were placed in distilled water (0.5 ml). The pH was recorded after 1 h. Apoproteins were identified by comparison to published values for their pI and by isoelectric focusing with purified apoproteins.
The various lipoprotein fractions were also assessed by double diffusion against anti-human albumin (Miles Laboratories Inc., Elkhart, Ind.) and anti-human LDL. The latter was prepared in rabbits by injection ofhuman LDL (d = 1.030-1.050 g/ml) in an equal mixture with Freund's adjuvant.
Protein was estimated by the method of Lowry et al. (20) with bovine serum albumin as a standard. Lipoprotein fractions and standards were extracted with diethyl ether after color development. The protein content in TMU extracts was determined as described by Kane (17) except that TMU was used in the standards.
Lipid analysis by gas-liquid chromatography. Plasma or lipoprotein fractions were assayed for triglycerides, esterified cholesterol, free cholesterol, and phospholipids by an automated gas chromatographic procedure as previously described (21) . For this purpose the plasma (50 Il) was digested under diethyl ether with phospholipase C (Clostrid-ium welchii), which converted the lecithins and sphingomyelins into the corresponding diglycerides and ceramides, and any lysolecithins into the monoglycerides. After extraction with chloroform-methanol, the mixed neutral lipids were treated with trimethylchlorosilane and hexamethyldisilazane, which converted any FFA into the trimethylsilyl esters, the free cholesterol, diglycerides, and ceramides into the corresponding trimethylsilyl ethers, and any monoglycerides into the ditrimethylsilyl ethers. The neutral lipid mixture was separated and quantitated in the presence of tridecanoin as internal standard by automated high-temperature gasliquid chromatography with 20 x 1/16-in i.d. stainless steel tubes that contained 3% OV-1 (a methyl siloxane polymer) on Gas-Chrom Q (100-200 mesh) (Applied Science Laboratories Inc., State College, Pa.). The gas chromatograph was the Hewlett-Packard automated gas chromatographic system 5700 A (Hewlett-Packard Co., Palo Alto, Calif.), which included an automatic sampler, low mass oven with temperature programmer, electronic integrator, and a dual flame-ionization detector. The integrator output was simultaneously recorded on a strip chart recorder and a punched paper tape that encoded the peak retention times and areas in computer-compatible code. The tape was subsequently used for off-line data processing by means of computer programs (21) . Appropriate calibration and conversion factors were used for differences in recovery, flame-ionization response, and the chemical form of analysis of the different plasma lipids. The precision of the methodology was 3-5% for the estimate of lipid classes, whereas the limit of detection of lipid classes was -10 ,ug/dl.
A paired t test was used to compare lipid results in plasma before, during, and after Intralipid administration.
RESULTS
Initial observations ( Fig. 1 with the amount of Intralipid infused (P < 0.001) over the time period. These observations prompted more detailed time-related studies to assess the effect of Intralipid on plasma lipids and lipoproteins in infants requiring TPN.
Plasma lipids. In Fig. 2 the changes in total lipid profiles of an infant are shown before Intralipid infusion (panel A); after 24 h (panel B) and after 2.5 mo (panel C) on Intralipid infusion; as well as 3 mo after discontinuation of Intralipid (panel D). Before infusion the major plasma lipid constituents were free cholesterol (C27), phospholipids (C34-C40), and cholesterol esters (C43 and C45). After 24 h of Intralipid infusion there was a marked increase in free cholesterol and phospholipid concentration but no increase in triglycerides (C50-C54). By 2.5 mo plant sterols became evident as the amounts of campesterol (C28) and ,8-sitosterol (C29) were more obvious than at 24 h of infusion. In this individual there was a marked decrease in cholesterol ester, but this was not a systematic change because increases in cholesterol esters were observed in several short-term studies (7 d To identify the early phases of free cholesterol and phospholipid accumulation, the plasma phospholipid and free cholesterol concentrations were followed (Fig. 3) (Fig. 3) .
Alterations in lipoprotein composition. The increments in plasma free cholesterol and phospholipid were confined almost entirely to an increase (sixfold) in the concentration of LDL (d = 1.006-1.063 g/ml as shown in Fig. 4) . No significant changes occurred in absolute amounts offree cholesterol and phospholipids in HDL and very low density lipoproteins (VLDL). After cessation of Intralipid (5 wk) the lipoprotein composition and concentrations had returned to preinfusion values with the exception of HDL. The average This suggestion was substantiated by agar electrophoresis where Lp-X migration is cathodal (Fig. 6) . Fig. 6 also shows the appearance of Lp-X on agar electrophoresis coinciding with the accumulation of free cholesterol and phospholipid in plasma during a 64-h infusion of Intralipid. Lp-X starts to appear at 16 h along with the parallel increases in free cholesterol and phospholipid (Fig. 3) , and accumulates progressively during the remainder of the study period as judged by the intensity of the Lp-X band. The 4 Composition of plasma lipoproteins (n = 5) before, during (7-10 d), and 6 wk after Intralipid infusion. The content of free cholesterol and phospholipid was significantly higher in LDL during Intralipid infusion (P < 0.01). The ratio of free cholesterol:esterified cholesterol was lower (P < 0.02) in HDL of neonates after infusion (0.45+0.09) than during infusion (3.48+0.51; mean+SEM).
presence of Lp-X before 16 h could not be demonstrated by the electrophoretic procedure.
Because the major accumulation of free cholesterol and phospholipid was in LDL fraction, and because Lp-X was apparent by agar electrophoresis, an attempt was made to isolate and characterize Lp-X using the technique of hydroxylapatite chromatography as described by Kostner et al. (14) . phosphate buffer a lipoprotein was isolated with a composition essentially equivalent to Lp-X isolated from a cholestatic patient (Table II) . After 6 d of Intralipid infusion the free cholesterol of Lp-X increased 30 +10 mg/dl (mean±+-SD) and represented -25% of the total free cholesterol in LDL.
The small amount ofprotein (6%) in Lp-X was entirely soluble in TMU, indicating the absence of apoB. No apoB was detected immunochemically, but albumin was detected after delipidation of the lipoprotein (data not shown). Further analysis by isoelectric focusing of the urea-soluble proteins of Lp-X revealed (Fig. 7) FIGuRE 6 Agar gel electrophoresis of plasma of a neonate at various stages ofIntralipid infusion ( Lp-X. To obtain sufficient material for analysis the LDL from 0.5 ml of plasma, from three neonates infused with Intralipid (2-4 g/kg body wt per d) for 6 d, was first separated by hydroxylapatite chromatography. After the cholesterol was determined in the 0.1 M and 0.65 M phosphate buffer eluates, these fractions were pooled for complete lipid and protein analyses. The amount of total cholesterol in the 0.1 M P04 and 0.65 M P04= fractions was 30+ 10 and 150+20 mg/100 ml, respectively. Recovery of lipoprotein cholesterol after hydroxylapatite chromatography was 90±5% (mean±SD). The amount of TMU-insoluble protein in LDL increased from 35.2 to 39.6 mg/100 ml in these subjects. § FC, free cholesterol; CE, cholesterol ester; TG, triglyceride; PL, phospholipid.
that a major protein focused at pl 6.0-6.2, which is characteristic for human albumin under these conditions. A series of bands focusing between a pl of 5.5 and 5.9 were identical to the pI of isomorphs of apoE from normal human VLDL. ApoCII and apoCIII were also identified. When expressed as a percentage of total, optical density on the gel albumin accounted for 50%, apoCII plus apoCIII for 30%, and apoE for 10%, with apoAI and unidentified peptides representing 5%. Small amounts of apoE and apoAl have been identified in Lp-X isolated by zonal ultracentrifugation from cholestatic plasma (23) . The residual lipoproteins of the LDL fraction eluted with 0.65 M phosphate buffer were abnormal (Table  II) . This fraction contained increased levels of free cholesterol, phospholipid, and TMU-soluble peptides, relative to normal LDL; but apoB, identified by immunodiffusion against anti-LDL and quantitated by the amount of protein insoluble in TMU, was still a major component. In a single analysis of LDL pooled from three subjects there was a 10% increase in apoB during an infusion for 6 d. Analyses of the urea-soluble proteins (Fig. 7) revealed that the TMU-soluble material was primarily composed ofapoE (60%) and apoCII plus apoCIII (30%) with minimal amounts of albumin and unidentified peptides. Rechromatography on hydroxylapatite of the residual LDL fraction did not give Lp-X material that could be eluted with 0.1 M phosphate buffer (data not shown). A similar particle has been observed in the LDL fraction of plasma from rats infused with Intralipid (24) .
Initial studies on plasma specimens from infants who had been discontinued from Intralipid for 5-6 wk (Fig. 4) indicated that the plasma lipoprotein concentration and composition had returned to essentially preinfusion concentrations. To study shorter time intervals, plasma specimens were obtained at daily intervals after cessation of Intralipid infusion. Both plasma free cholesterol and phospholipid began to decrease within 24 h of termination of the infusion. By 96 h the free cholesterol levels had almost returned to preinfusion levels and plant sterols had disappeared, whereas plasma phospholipid levels were still somewhat elevated (Fig. 8) (7) (8) (9) and experimental animals (24) .
On the basis of the cholesterol content of the Intra- formation of Lp-X. (35, 36) , presumably a result of increased human hydroxymethylglutaryl-coenzyme A reductase activity (37) . In our study, Lp-X was discerned after 16 h of Intralipid infusion when the increase in plasma phospholipid was 50-70% above preinfusion levels (Fig. 6) . Although Lp-X particles may be present but not detected at earlier times it is probable that the initial increment in phospholipid was accommodated by association with preexisting lipoproteins. This view is consistent with the data of Thompson et al. (8) who examined serum lipoproteins after a 4-h infusion of50 g of Intralipid (containing 6.0 g of phospholipid) into healthy adults and observed no Lp-X formation. It is obvious that a much larger relative load ofphospholipid must be administered and for longer periods of time before Lp-X appears; e.g., during TPN with Intralipid (6) .
The exact origin of Lp-X is not established. Manzato et al. (38) suggested that in patients with cholestasis Lp-X was derived from bile lipoproteins that contained phospholipid, cholesterol, and albumin, which refluxed into the blood stream and acquired C-apopeptides. In familial LCAT deficiency the accumulation of Lp-X has been attributed to a failure to esterify cholesterol (39) , which would be expected to lead to elevation of both free cholesterol and phospholipid levels. The extracellular formation of Lp-X has been reported in perfused livers in rats with cholestasis (40) . Although the exact process responsible for Lp-X formation during Intralipid infusion cannot be discerned from this and previous (24) studies, an extracellular, physicochemical mechanism is proposed. As the level of plasma phospholipids exceeds the capacity for clearance, free cholesterol is mobilized by the lecithin-mesophase resulting in a stable phospholipid-cholesterol particle, which competes successfully with other lipoproteins for the apoproteins, and forming Lp-X. Alternatively, the apopeptides may be mobilized by the lecithin mesophase particles before their equilibration with free cholesterol. This hypothesis requires experimental confirmation.
It is significant that the rate of clearance of Lp-X after cessation of Intralipid infusion was similar to the clearance of Lp-X in cholestatic patients after operations to correct bile duct obstruction (41) or after plasma transfusion to patients with LCAT deficiency (42) . In these instances a 50% reduction in Lp-X occurred in 2-3 d. In our study over 95% of the Lp-X disappeared in 2-4 d. These findings suggest that clearance of Lp-X is LCAT dependent because a reduction in Lp-X precursor (Intralipid mesophase) load or increasing enzymatic activities Lp-X levels are reduced. Furthermore the fact that Lp-X occurred in conjunction with an absolute or relative deficiency in LCAT enzyme, whose function is entirely extracellular, supports the view that Lp-X occurs as an extracellular physicochemical event.
We have continued to use Intralipid (10%) in the management of infants who cannot be fed in the normal manner. The absence of significant hemolysis and of renal disease clinically and at postmortem during short-term infusions, suggests that tissue changes were not associated with the presence of Lp-X. The effect of long-term infusions are yet to be established and deserve attention in view of the nephropathy associated with the Lp-X accumulation of LCAT deficiency.
